Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss its financial results for the second quarter ended June 30, 2026, along with recent business progress.
According to Relmada, U.S. participants can dial 1-800-717-1738, international participants can dial 1-646-307-1865, and a webcast will be accessible via the Investors section of the company’s website, where a replay will also be available.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings date notice: RLMD -12.08% in the Jul 16 session
In the Jul 16 session, RLMD declined 12.08%, reflecting a significant negative market reaction. Argus tracked a trough of -13.0% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Earnings date notice | Neutral | +6.9% | Set timing for Q1 2026 results call and webcast with updates. |
| Mar 12 | Earnings date notice | Neutral | -2.7% | Announced Q4 2025 results date and related conference call details. |
| Nov 07 | Earnings date notice | Neutral | +1.5% | Scheduled Q3 2025 results release and webcast with dial-in access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Around earnings date notices, the stock has more often posted a modest positive move than a decline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.
Conference Call and Webcast Information:
- Date: Thursday, August 6, 2026 at 4:30 PM ET
- Participant Dial-in (US): 1-800-717-1738
- Participant Dial-in (International): 1-646-307-1865
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
